source
- FDA rejects Capricor’s Duchenne cell therapy after trials show no benefitThe Food and Drug Administration announced that it is rejecting deramiocel, a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The treatment was aimed at teenage an…
- Sanofi considers Insmed acquisition as FDA criticizes J&J bladder cancer drug claims; Japan eyes higher drug pricesSanofi is reportedly evaluating a possible takeover of Insmed, signaling continued consolidation activity in the biotech sector. The U.S. Food and Drug Administration has issued a warning to Johns…